Ziprasidone
As of the edition of 20 October 2026, Ziprasidone is a small molecule: marketed, first approved in 2001 (US); acts on DRD2, HTR2A and HTR2C; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2002
- Kind
- Small molecule
- Brand name
- Geodon
- First approved
- 5 February 2001 (US)
- Approvals on record
- 7 in 2 regions
- Holder of the most recent approval
- Pfizer; 3 holders in all
- Registered trials
- 88, 15 stopped early
- Disease areas
- Mental health; Nervous system; Nutrition and metabolism; Hormones; Bones, joints and muscles; Infections
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Ziprasidone.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 9 | 0 | 2 |
| Phase 1 | 4 | 3 | 1 | 0 |
| Phase 2 | 9 | 8 | 0 | 0 |
| Phase 3 | 27 | 19 | 0 | 8 |
| Phase 4 | 36 | 27 | 0 | 5 |
| All trials | 88 |